<SEC-DOCUMENT>0001231919-25-000559.txt : 20251128
<SEC-HEADER>0001231919-25-000559.hdr.sgml : 20251128
<ACCEPTANCE-DATETIME>20251128152543
ACCESSION NUMBER:		0001231919-25-000559
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251128
DATE AS OF CHANGE:		20251128

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88266
		FILM NUMBER:		251535412

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		EIN:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001193125-24-029534</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>2</amendmentNo>
	      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/25/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001501756</issuerCik>        <issuerName>ADVERUM BIOTECHNOLOGIES, INC.</issuerName>        <issuerCusip>00773U207</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>100 CARDINAL WAY</com:street1>
                    <com:city>REDWOOD CITY</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94063</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4288949.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4288949.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4288949.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>19.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4288949.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4288949.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4288949.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>19.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4288949.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4288949.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4288949.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>19.4</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>216964.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>216964.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>216964.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>216964.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>216964.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>216964.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.
</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>216964.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>216964.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>216964.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>504849.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>504849.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>504849.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.3</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>504849.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>504849.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>504849.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.3</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>504849.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>504849.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>504849.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.3</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>522768.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>522768.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>522768.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>522768.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>522768.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>522768.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>522768.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>522768.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>522768.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.4</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.
</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>216964.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>216964.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>216964.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 216,964 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>216964.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>216964.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>216964.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 216,964 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>ADVERUM BIOTECHNOLOGIES, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>100 CARDINAL WAY, REDWOOD CITY, CA, 94063.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P.  ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal place of business for each of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

FLSPF directly holds 4,288,949 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.

FLS X directly holds 216,964 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.

FLS XI directly holds 504,849 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.

FLS XII directly holds 522,768 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.

Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person.</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1 Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C. </title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C. </title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C. </title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C.</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>11/28/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-11282025_081145.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-11282025_081145.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px" align="right"><br></p>
<p style="margin:0px" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px" align="justify">Pursuant to Rule&nbsp;13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule&nbsp;13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Adverum Biotechnologies, Inc.</p>
<p style="margin:0px; text-indent:48px" align="justify">&nbsp;</p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XII, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XII, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XII, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XII, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XII, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XII, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Gordon Empey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Gordon Empey, General Counsel</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James N. Topper</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Patrick J. Heron</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;November 28, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Steve R. Bailey, as Attorney-in-Fact</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">*<b style="font-family:TimesNewRomanPSMT,Times New Roman; font-size:12pt;font-weight:normal;"> </b>This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
